Skip to main content
Clinical Trials/ISRCTN18135766
ISRCTN18135766
Completed
未知

Effectiveness of hypertension management with an amlodipine and perindopril arginine-based strategy in Morocco

SERVIER (Morocco)0 sites1,614 target enrollmentApril 5, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
SERVIER (Morocco)
Enrollment
1614
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 5, 2024
End Date
March 15, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
SERVIER (Morocco)

Eligibility Criteria

Inclusion Criteria

  • 1\. Men or women aged \=18 years who document informed consent.
  • 2\. Hypertensive patients previously treated with amlodipine monotherapy, uncontrolled and for whom the treating physician decides to add perindopril arginine.

Exclusion Criteria

  • 1\.Age \< 18 years
  • 2\.Pregnancy, breastfeeding or possibility of becoming pregnant during the study
  • 3\.Current participation in another randomized study or within the previous 3 months
  • 4\.Known symptomatic orthostatic hypotension
  • 5\.Known hyperkalemia or hypokalemia
  • 6\.History of arterial hypertension known to be resistant to the free combination or in a single tablet with perindopril and calcium channel blockers or contraindications to treatment with perindopril or amlodipine
  • 7\.Known secondary hypertension or complicated hypertension
  • 8\.Known renal insufficiency: patients with a creatinine clearance value classifying them as moderate or severe renal insufficiency according to the national or international classification of chronic renal insufficiency or bilateral stenosis of the renal artery or stenosis at solitary kidney or history of gout
  • 9\.Known complicated liver disease
  • 10\.Chronic pancreatitis

Outcomes

Primary Outcomes

Not specified

Similar Trials